Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Wednesday, September 16, 2026

Emerging Treatments for Parkinson’s Disease: Adaptive DBS, Gene, and Cell Therapy

 

Will your competent? doctor be doing something with this because of your risk of Parkinsons post stroke? Oh NO, NOTHING DOING! So, INCOMPETENCE REIGNS AGAIN! Your doctor is becoming an expert at incompetence and your board of directors is so incompetent they can't recognize it in their hospital! 

Parkinson’s Disease May Have Link to Stroke March 2017 

The latest here:

Emerging Treatments for Parkinson’s Disease: Adaptive DBS, Gene, and Cell Therapy

Parkinson’s disease is a progressive neurodegenerative disorder characterized by motor and nonmotor symptoms (autonomic, cognitive, and psychiatric). We will review emerging therapeutic strategies across deep brain stimulation (DBS), cell therapy, and gene therapy. First, DBS uses implanted intracranial electrodes to deliver chronic electrical stimulation aimed at normalizing network function. Recent devices enable real-time neural recording and adaptive stimulation that responds to sensed biomarkers. Second, we will examine efforts to rebuild dopaminergic circuitry using autologous dopaminergic cell transplantation. Finally, we will discuss gene therapy, with a focus on AAV2-mediated GDNF delivery, to support surviving dopaminergic neurons and potentially slow degeneration.Todd Herrington, MD, PhD
Assistant Professor of Neurology, Harvard Medical School
Neurologist, Massachusetts General Hospital

Dr. Todd Herrington is a movement disorders neurologist, neurophysiologist, and the director of the Deep Brain Stimulation (DBS) program at Massachusetts General Hospital. He completed his MD through the Health Sciences and Technology program and his PhD through the Neuroscience program at Harvard Medical School. Herrington completed a residency at the Mass General Brigham Neurology program, where he was chief resident, followed by fellowship training in movement disorders and intraoperative neurophysiology.

Dr. Herrington has a focused clinical practice caring for patients with movement disorders and a clinical-translational research program aimed at understanding the mechanisms of DBS, the development of adaptive approaches to stimulation, and the translation of that work into new, more effective treatments. In addition, he collaborates to advance gene and cell therapy approaches to treat neurodegenerative disease.

Objectives

After this presentation, participants will be able to:

Describe the cardinal clinical features of Parkinson's disease
Describe advances in DBS, gene, and cell therapy approaches to treat Parkinson's disease

Sponsored by:

Spencer Fox Eccles School of Medicine at the University of Utah, Department of Pathology, and ARUP Laboratories

No comments:

Post a Comment